Mohammad Bohlooly‐Y

Optimised genome editing for precise DNA insertion and substitution using Prime Editors in zebrafish

This study uses Prime Editors in zebrafish to achieve precise DNA insertion and substitution without exogenous donor DNA, showing higher efficiency for short modifications with nuclease-based PEn.

Integrative Analysis of Left Ventricle and Epicardial Adipose Tissue Identifies SDHA and OGDH as Candidate Targets for Ischemic Heart Disease

Simultaneous inhibition of DNA-PK and Pol{Theta} improves integration efficiency and precision of genome editing

This study identifies AZD7648 and Pol{Theta} inhibitors as a combination (2iHDR) that enhances CRISPR-Cas9 integration efficiency and precision by targeting DNA-PK and MMEJ repair pathways.

A combined human in silico and CRISPR/Cas9-mediated in vivo zebrafish based approach for supporting gene target validation in early drug discovery

The paper identifies three genes associated with heart failure using human exome sequencing and validates their roles in cardiovascular function using zebrafish CRISPR/Cas9 mutagenesis.

Human genetic evidence supports MAP3K15 inhibition as a therapeutic strategy for diabetes

The paper identifies MAP3K15 as a protective gene for diabetes through genetic analysis and shows its inhibition could be a therapeutic strategy.

ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment

This paper introduces an inducible CRISPR-Cas9 system for preclinical drug discovery, enabling controlled genome editing in mice to model cancer and test therapies.

In vivo CRISPR-Cas gene editing with no detectable genome-wide off-target mutations

The paper introduces VIVO, a method to detect off-target mutations from in vivo CRISPR-Cas editing, showing that well-designed gRNAs can edit efficiently without detectable off-targets.